Morpholino

MO2-cftr

ID
ZDB-MRPHLNO-101104-2
Name
MO2-cftr
Previous Names
  • CFTR Trans MO (1)
Target
Sequence
5' - CATCCTCCACAGGTGATCTCTGCAT - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
Translation-blocking MO.
Genome Resources
None
Target Location
Genomic Features
No data available
Expression
Gene expression in Wild Types + MO2-cftr
Phenotype
Phenotype resulting from MO2-cftr
Phenotype Fish Figures
common myeloid progenitor tal1 expression decreased amount, abnormal AB + MO2-cftr Fig. S6 with image from Sun et al., 2018
common myeloid progenitor myb expression decreased amount, abnormal AB + MO2-cftr Fig. S10 with image from Sun et al., 2018
common myeloid progenitor runx1 expression decreased amount, abnormal AB + MO2-cftr Fig. S10 with image from Sun et al., 2018
erythroid lineage cell hbbe3 expression decreased amount, abnormal AB + MO2-cftr Fig. S10 with image from Sun et al., 2018
erythroid lineage cell gata1a expression decreased amount, abnormal AB + MO2-cftr Fig. S6 with image from Sun et al., 2018
intermediate cell mass of mesoderm runx1 expression decreased amount, abnormal AB + MO2-cftr Fig. S10 with image from Sun et al., 2018
intermediate cell mass of mesoderm hbbe3 expression decreased amount, abnormal AB + MO2-cftr Fig. S10 with image from Sun et al., 2018
intermediate cell mass of mesoderm myb expression decreased amount, abnormal AB + MO2-cftr Fig. S10 with image from Sun et al., 2018
lateral plate mesoderm lmo2 expression decreased amount, abnormal AB + MO2-cftr Fig. S10 with image from Sun et al., 2018
lateral plate mesoderm tal1 expression decreased amount, abnormal AB + MO2-cftr Fig. S7 with imageFig. S10 with imageFig. S14 with image from Sun et al., 2018
lateral plate mesoderm gata2a expression decreased amount, abnormal AB + MO2-cftr Fig. S10 with image from Sun et al., 2018
lateral plate mesoderm gata1a expression decreased amount, abnormal AB + MO2-cftr Fig. S10 with imageFig. S14 with image from Sun et al., 2018
mesoderm cdx4 expression decreased amount, abnormal AB + MO2-cftr Fig. S12 with image from Sun et al., 2018
mesoderm hoxa9a expression decreased amount, abnormal AB + MO2-cftr Fig. S12 with image from Sun et al., 2018
myeloid cell lcp1 expression decreased amount, abnormal AB + MO2-cftr Fig. S6 with image from Sun et al., 2018
myeloid lineage restricted progenitor cell spi1b expression decreased amount, abnormal AB + MO2-cftr Fig. S10 with image from Sun et al., 2018
whole organism lef1 expression decreased amount, abnormal AB + MO2-cftr Fig. 3 with image from Sun et al., 2018
whole organism myca expression decreased amount, abnormal AB + MO2-cftr Fig. 3 with image from Sun et al., 2018
Phenotype of all Fish created by or utilizing MO2-cftr
Phenotype Fish Conditions Figures
whole organism il1b expression amount, ameliorated AB + MO1-cftr + MO2-cftr viral treatment by injection: Pseudomonas phage vB_PaeM_E215, viral treatment by injection: Pseudomonas phage vB_PaeM_E217, viral treatment by injection: Pseudomonas phage vB_PaeP_PYO2, viral treatment by injection: Pseudomonas phage vB_PaeP_DEV Fig. 4 from Cafora et al., 2019
whole organism decreased life span, ameliorated AB + MO1-cftr + MO2-cftr viral treatment by injection: Pseudomonas phage vB_PaeM_E215, viral treatment by injection: Pseudomonas phage vB_PaeM_E217, bacterial treatment by injection: Pseudomonas aeruginosa, viral treatment by injection: Pseudomonas phage vB_PaeP_DEV, viral treatment by injection: Pseudomonas phage vB_PaeP_PYO2, chemical treatment: ciprofloxacin Fig. 5 from Cafora et al., 2019
whole organism tnfa expression increased amount, abnormal AB + MO1-cftr + MO2-cftr control Fig. 4 from Cafora et al., 2019
heart looping disrupted, abnormal AB + MO1-cftr + MO2-cftr standard conditions Fig. 1 from Cafora et al., 2020
defense response to bacterium decreased efficacy, abnormal AB + MO1-cftr + MO2-cftr bacterial treatment by injection: Pseudomonas aeruginosa Fig. 2 with imageFig. 3 with image from Cafora et al., 2019
defense response to bacterium decreased efficacy, abnormal AB + MO1-cftr + MO2-cftr bacterial treatment by injection: Pseudomonas aeruginosa Fig. 4 from Cafora et al., 2020
whole organism tnfa expression increased amount, abnormal AB + MO1-cftr + MO2-cftr viral treatment by injection: Pseudomonas phage vB_PaeM_E215, viral treatment by injection: Pseudomonas phage vB_PaeM_E217, bacterial treatment by injection: Pseudomonas aeruginosa, viral treatment by injection: Pseudomonas phage vB_PaeP_DEV, viral treatment by injection: Pseudomonas phage vB_PaeP_PYO2 Fig. 3 with image from Cafora et al., 2019
defense response to bacterium increased efficacy, abnormal AB + MO1-cftr + MO2-cftr viral treatment by injection: Pseudomonas phage vB_PaeM_E215, viral treatment by injection: Pseudomonas phage vB_PaeM_E217, bacterial treatment by injection: Pseudomonas aeruginosa, viral treatment by injection: Pseudomonas phage vB_PaeP_DEV, viral treatment by injection: Pseudomonas phage vB_PaeP_PYO2 Fig. 3 with image from Cafora et al., 2019
heart looping decreased occurrence, abnormal AB + MO1-cftr + MO2-cftr control Fig. 2 with image from Cafora et al., 2019
whole organism decreased life span, ameliorated AB + MO1-cftr + MO2-cftr bacterial treatment by injection: Pseudomonas aeruginosa, chemical treatment: ciprofloxacin Fig. 5 from Cafora et al., 2019
whole organism decreased life span, ameliorated AB + MO1-cftr + MO2-cftr viral treatment by injection: Pseudomonas phage vB_PaeM_E215, viral treatment by injection: Pseudomonas phage vB_PaeM_E217, bacterial treatment by injection: Pseudomonas aeruginosa, viral treatment by injection: Pseudomonas phage vB_PaeP_DEV, viral treatment by injection: Pseudomonas phage vB_PaeP_PYO2 Fig. 3 with imageFig. 5 from Cafora et al., 2019
whole organism il1b expression decreased amount, abnormal AB + MO1-cftr + MO2-cftr bacterial treatment by injection: Pseudomonas aeruginosa Fig. 2 with image from Cafora et al., 2019
whole organism decreased life span, exacerbated AB + MO1-cftr + MO2-cftr bacterial treatment by injection: Pseudomonas aeruginosa Fig. 3 with image from Cafora et al., 2019
heart mislocalised, abnormal AB + MO1-cftr + MO2-cftr standard conditions Fig. 1 from Cafora et al., 2020
whole organism il1b expression increased amount, abnormal AB + MO1-cftr + MO2-cftr control Fig. 4 from Cafora et al., 2019
whole organism tnfa expression amount, ameliorated AB + MO1-cftr + MO2-cftr viral treatment by injection: Pseudomonas phage vB_PaeM_E215, viral treatment by injection: Pseudomonas phage vB_PaeM_E217, viral treatment by injection: Pseudomonas phage vB_PaeP_PYO2, viral treatment by injection: Pseudomonas phage vB_PaeP_DEV Fig. 4 from Cafora et al., 2019
whole organism tnfa expression increased amount, abnormal AB + MO1-cftr + MO2-cftr bacterial treatment by injection: Pseudomonas aeruginosa Fig. 3 with image from Cafora et al., 2019
whole organism il1b expression increased amount, abnormal AB + MO1-cftr + MO2-cftr bacterial treatment by injection: Pseudomonas aeruginosa Fig. 3 with image from Cafora et al., 2019
whole organism dead, abnormal AB + MO1-cftr + MO2-cftr bacterial treatment by injection: Pseudomonas aeruginosa Fig. 3 from Cafora et al., 2020
defense response to bacterium disrupted, abnormal AB + MO1-cftr + MO2-cftr bacterial treatment: Pseudomonas aeruginosa PA14 Fig. 4 from Phennicie et al., 2010
respiratory burst involved in inflammatory response disrupted, abnormal AB + MO1-cftr + MO2-cftr standard conditions Fig. 2 from Phennicie et al., 2010
whole organism decreased life span, abnormal AB + MO1-cftr + MO2-cftr bacterial treatment by injection: Pseudomonas aeruginosa Fig. 3 from Cafora et al., 2020
whole organism tnfa expression increased amount, abnormal AB + MO1-cftr + MO2-cftr bacterial treatment by injection: Pseudomonas aeruginosa Fig. 5 from Cafora et al., 2020
whole organism il1b expression amount, ameliorated AB + MO1-cftr + MO2-cftr viral treatment by injection: Pseudomonas phage vB_PaeM_E215, viral treatment by injection: Pseudomonas phage vB_PaeM_E217, bacterial treatment by injection: Pseudomonas aeruginosa, viral treatment by injection: Pseudomonas phage vB_PaeP_DEV, viral treatment by injection: Pseudomonas phage vB_PaeP_PYO2 Fig. 3 with image from Cafora et al., 2019
determination of pancreatic left/right asymmetry disrupted, abnormal AB + MO1-cftr + MO2-cftr standard conditions Fig. 1 from Cafora et al., 2020
determination of pancreatic left/right asymmetry decreased occurrence, abnormal AB + MO1-cftr + MO2-cftr control Fig. 2 with image from Cafora et al., 2019
whole organism tnfa expression decreased amount, abnormal AB + MO1-cftr + MO2-cftr bacterial treatment by injection: Pseudomonas aeruginosa Fig. 2 with image from Cafora et al., 2019
whole organism decreased life span, abnormal AB + MO1-cftr + MO2-cftr bacterial treatment by injection: Pseudomonas aeruginosa Fig. 5 from Cafora et al., 2019
determination of liver left/right asymmetry disrupted, abnormal AB + MO1-cftr + MO2-cftr standard conditions Fig. 1 from Cafora et al., 2020
whole organism il1b expression increased amount, abnormal AB + MO1-cftr + MO2-cftr bacterial treatment by injection: Pseudomonas aeruginosa Fig. 5 from Cafora et al., 2020
determination of liver left/right asymmetry decreased occurrence, abnormal AB + MO1-cftr + MO2-cftr control Fig. 2 with image from Cafora et al., 2019
myeloid lineage restricted progenitor cell spi1b expression decreased amount, abnormal AB + MO2-cftr standard conditions Fig. S10 with image from Sun et al., 2018
lateral plate mesoderm lmo2 expression decreased amount, abnormal AB + MO2-cftr standard conditions Fig. S10 with image from Sun et al., 2018
mesoderm cdx4 expression decreased amount, abnormal AB + MO2-cftr standard conditions Fig. S12 with image from Sun et al., 2018
common myeloid progenitor runx1 expression decreased amount, abnormal AB + MO2-cftr standard conditions Fig. S10 with image from Sun et al., 2018
common myeloid progenitor tal1 expression decreased amount, abnormal AB + MO2-cftr standard conditions Fig. S6 with image from Sun et al., 2018
lateral plate mesoderm gata2a expression decreased amount, abnormal AB + MO2-cftr standard conditions Fig. S10 with image from Sun et al., 2018
lateral plate mesoderm tal1 expression decreased amount, abnormal AB + MO2-cftr standard conditions Fig. S7 with imageFig. S10 with imageFig. S14 with image from Sun et al., 2018
mesoderm hoxa9a expression decreased amount, abnormal AB + MO2-cftr standard conditions Fig. S12 with image from Sun et al., 2018
intermediate cell mass of mesoderm hbbe3 expression decreased amount, abnormal AB + MO2-cftr standard conditions Fig. S10 with image from Sun et al., 2018
intermediate cell mass of mesoderm myb expression decreased amount, abnormal AB + MO2-cftr standard conditions Fig. S10 with image from Sun et al., 2018
intermediate cell mass of mesoderm runx1 expression decreased amount, abnormal AB + MO2-cftr standard conditions Fig. S10 with image from Sun et al., 2018
erythroid lineage cell hbbe3 expression decreased amount, abnormal AB + MO2-cftr standard conditions Fig. S10 with image from Sun et al., 2018
whole organism myca expression decreased amount, abnormal AB + MO2-cftr standard conditions Fig. 3 with image from Sun et al., 2018
erythroid lineage cell gata1a expression decreased amount, abnormal AB + MO2-cftr standard conditions Fig. S6 with image from Sun et al., 2018
whole organism lef1 expression decreased amount, abnormal AB + MO2-cftr standard conditions Fig. 3 with image from Sun et al., 2018
myeloid cell lcp1 expression decreased amount, abnormal AB + MO2-cftr standard conditions Fig. S6 with image from Sun et al., 2018
common myeloid progenitor myb expression decreased amount, abnormal AB + MO2-cftr standard conditions Fig. S10 with image from Sun et al., 2018
lateral plate mesoderm gata1a expression decreased amount, abnormal AB + MO2-cftr standard conditions Fig. S10 with imageFig. S14 with image from Sun et al., 2018
neutrophil chemotaxis disrupted, abnormal i114Tg + MO1-cftr + MO2-cftr bacterial treatment: Pseudomonas aeruginosa PA14 Fig. 3 from Phennicie et al., 2010
neutrophil decreased amount, abnormal i114Tg + MO1-cftr + MO2-cftr bacterial treatment: Pseudomonas aeruginosa PA14 Fig. 3 from Phennicie et al., 2010
Citations